摘要
Gastrointestinal (GI) tumor is a serious disease with high mortality rates and morbidity rates worldwide. Chemotherapy is a key treatment for GI, however, systematic side effects and inevitable drug resistance complicate the situation. In the process of therapy, P-glycoprotein (P-gp) could remove chemotherapy drugs from cells, thus causing multi-drug resistance. Chemodynamic therapy (CDT) utilizing Fenton chemistry has been used for cancer therapy, along with various combination therapies. The reactive oxygen species produced by CDT could inhibit P-gp's efflux pump function, which reduce chemoagents excretion and reverse drug resistance. In the present study, we developed novel nanocrystals (Cu2O@Pt NCs) to overcome drug resistance by reducing mitochondria-derived ATP through chemo/CDT in GI cancer. Furthermore, in vivo results in tumor-bearing mice demonstrated that treatment with Cu2O@Pt NCs with CDT and chemotherapy could achieve the most effective antitumor therapeutic effect with the least amounts of adverse effects. As a result, Cu2O@Pt NCs could provide a promising strategy for chemo/CDT-synergistic therapy.
学科与关键词
- Nanocatalytic Theranostics with Glutathione Depletion and Enhanced Reactive Oxygen Species Generation for Efficient Cancer Therapy.Fu, Lian-Hua; Wan, Yilin; Qi, Chao; He, Jin; Li, Chunying; Yang, Chen; Xu, Han; Lin, Jing; Huang, PengAdvanced Materials, 2021, 33(7): e2006892.
- Remodeling endogenous H2S microenvironment in colon cancer to enhance chemodynamic therapyLiu, Donglin; Liu, Mengjun; Wan, Ying; Zhou, Xuesu; Yang, Shiping*; An, Lu; Huang, Gang*; Tian, Qiwei*Chemical Engineering Journal, 2021, 422: 130098.
- Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP)Guo, Weihong*; Chen, Zhian; Feng, Xiaoli; Shen, Guodong; Huang, Huilin; Liang, Yanrui; Zhao, Bingxia*; Li, Guoxin*; Hu, Yanfeng*JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19(1): 146.被引 33
